https://ymaho.com/imp761-first-lag-3-agonist-passes-phase-i-in-autoimmune-diseases
Analysis of IMP761 data from Immutep at EULAR 2026: a new class of drugs for treating rheumatoid arthritis without total immunosuppression. Safety, mechanism, and prospects. Read more.